Kopran Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 8:57 am

Competitors of Kopran Ltd

All Competitor Stocks of Kopran Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:15 pm

Below is a detailed analysis of the quarterly data for Kopran Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 135.22 Cr.. The value appears to be declining and may need further review. It has decreased from 172.36 Cr. (Mar 2025) to 135.22 Cr., marking a decrease of 37.14 Cr..
• For Expenses, as of Jun 2025, the value is 121.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 155.27 Cr. (Mar 2025) to 121.09 Cr., marking a decrease of 34.18 Cr..
• For Operating Profit, as of Jun 2025, the value is 14.13 Cr.. The value appears to be declining and may need further review. It has decreased from 17.09 Cr. (Mar 2025) to 14.13 Cr., marking a decrease of 2.96 Cr..
• For OPM %, as of Jun 2025, the value is 10.45%. The value appears strong and on an upward trend. It has increased from 9.92% (Mar 2025) to 10.45%, marking an increase of 0.53%.
• For Other Income, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 3.26 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.70 Cr..
• For Interest, as of Jun 2025, the value is 2.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.77 Cr. (Mar 2025) to 2.54 Cr., marking a decrease of 0.23 Cr..
• For Depreciation, as of Jun 2025, the value is 4.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.87 Cr. (Mar 2025) to 4.26 Cr., marking an increase of 0.39 Cr..
• For Profit before tax, as of Jun 2025, the value is 9.89 Cr.. The value appears to be declining and may need further review. It has decreased from 13.71 Cr. (Mar 2025) to 9.89 Cr., marking a decrease of 3.82 Cr..
• For Tax %, as of Jun 2025, the value is 24.67%. The value appears to be improving (decreasing) as expected. It has decreased from 29.39% (Mar 2025) to 24.67%, marking a decrease of 4.72%.
• For Net Profit, as of Jun 2025, the value is 7.45 Cr.. The value appears to be declining and may need further review. It has decreased from 9.68 Cr. (Mar 2025) to 7.45 Cr., marking a decrease of 2.23 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.54. The value appears to be declining and may need further review. It has decreased from 2.01 (Mar 2025) to 1.54, marking a decrease of 0.47.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:00 am

Growth

Last Updated: September 5, 2025, 9:15 am

Balance Sheet

Last Updated: September 10, 2025, 1:58 pm

Below is a detailed analysis of the balance sheet data for Kopran Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 48.00 Cr..
• For Reserves, as of Mar 2025, the value is 470.00 Cr.. The value appears strong and on an upward trend. It has increased from 443.00 Cr. (Mar 2024) to 470.00 Cr., marking an increase of 27.00 Cr..
• For Borrowings, as of Mar 2025, the value is 148.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 99.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 49.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 178.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2024) to 178.00 Cr., marking an increase of 25.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 844.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 743.00 Cr. (Mar 2024) to 844.00 Cr., marking an increase of 101.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 208.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2024) to 208.00 Cr., marking an increase of 26.00 Cr..
• For CWIP, as of Mar 2025, the value is 113.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Mar 2024) to 113.00 Cr., marking an increase of 16.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 522.00 Cr.. The value appears strong and on an upward trend. It has increased from 465.00 Cr. (Mar 2024) to 522.00 Cr., marking an increase of 57.00 Cr..
• For Total Assets, as of Mar 2025, the value is 844.00 Cr.. The value appears strong and on an upward trend. It has increased from 743.00 Cr. (Mar 2024) to 844.00 Cr., marking an increase of 101.00 Cr..

Notably, the Reserves (470.00 Cr.) exceed the Borrowings (148.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Kopran Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
• For Diluted EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.21. This value is within the healthy range. It has decreased from 13.24 (Mar 24) to 11.21, marking a decrease of 2.03.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 130.39. It has increased from 127.48 (Mar 24) to 130.39, marking an increase of 2.91.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 18.47 (Mar 24) to 15.92, marking a decrease of 2.55.
• For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 15.79 (Mar 24) to 12.69, marking a decrease of 3.10.
• For PBT / Share (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 14.01 (Mar 24) to 10.76, marking a decrease of 3.25.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
• For PBDIT Margin (%), as of Mar 25, the value is 12.21. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 12.21, marking a decrease of 2.27.
• For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 12.38 (Mar 24) to 9.73, marking a decrease of 2.65.
• For PBT Margin (%), as of Mar 25, the value is 8.25. This value is below the healthy minimum of 10. It has decreased from 10.99 (Mar 24) to 8.25, marking a decrease of 2.74.
• For Net Profit Margin (%), as of Mar 25, the value is 6.12. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 7.43, marking a decrease of 2.94.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.04, marking a decrease of 3.47.
• For Return On Assets (%), as of Mar 25, the value is 4.56. This value is below the healthy minimum of 5. It has decreased from 6.85 (Mar 24) to 4.56, marking a decrease of 2.29.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.28, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.88 (Mar 24) to 0.79, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.76, marking a decrease of 0.32.
• For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.18, marking a decrease of 0.26.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.09. This value is within the healthy range. It has increased from 2.93 (Mar 24) to 4.09, marking an increase of 1.16.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.51. This value is within the healthy range. It has increased from 28.38 (Mar 24) to 37.51, marking an increase of 9.13.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.71. This value is within the healthy range. It has increased from 22.65 (Mar 24) to 26.71, marking an increase of 4.06.
• For Earning Retention Ratio (%), as of Mar 25, the value is 62.49. This value is within the healthy range. It has decreased from 71.62 (Mar 24) to 62.49, marking a decrease of 9.13.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.29. This value exceeds the healthy maximum of 70. It has decreased from 77.35 (Mar 24) to 73.29, marking a decrease of 4.06.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 8.23. This value is within the healthy range. It has decreased from 10.36 (Mar 24) to 8.23, marking a decrease of 2.13.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has decreased from 6.93 (Mar 24) to 5.13, marking a decrease of 1.80.
• For Enterprise Value (Cr.), as of Mar 25, the value is 967.40. It has decreased from 1,330.79 (Mar 24) to 967.40, marking a decrease of 363.39.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 2.17 (Mar 24) to 1.54, marking a decrease of 0.63.
• For EV / EBITDA (X), as of Mar 25, the value is 12.58. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 12.58, marking a decrease of 2.37.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
• For Retention Ratios (%), as of Mar 25, the value is 62.48. This value is within the healthy range. It has decreased from 71.61 (Mar 24) to 62.48, marking a decrease of 9.13.
• For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.63, marking a decrease of 0.91.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness